Corwave
- Company typePrivate
- Founded2012
- HeadquartersParis, France
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Corwave firmographics
Firmographics- Name
- Corwave
- Legal name
- CorWave SA
- Website
- https://corwave.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Corwave industry classification
Industry- Product category
- Cardiac Assist Devices (LVAD)
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)
- akta.pro secondary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
Keywords
Where Corwave is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Corwave business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others
Revenue model
- Cardiac Assist Devices (pre-commercial): CorWave is a clinical-stage company that has not yet generated commercial revenue. Its LVAD device is investigational and not approved for commercial use in any country. The company is preparing for pivotal trials and eventual commercialization of its LVAD and Nemo products.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Corwave product offering
Product offeringCore offering
CorWave is a clinical-stage medical device company developing implantable cardiac assist pumps based on its proprietary wave membrane technology. The flagship offering is the CorWave LVAS (Left Ventricular Assist System), an implantable LVAD that uses an undulating membrane to produce physiological pulsatile blood flow for patients with advanced heart failure. A second product, Nemo, extends the wave membrane platform to mini-invasive circulatory support applications. All products are currently investigational and not approved for commercial use in any country.
Product overview
CorWave is a clinical-stage medical device company that has developed a portfolio of cardiac assist products centered on its proprietary wave membrane technology. The core technology is the Wave Membrane, which provides pulsatile blood flow by mimicking the undulating motion of marine animals. The primary product is the CorWave LVAS (Left Ventricular Assist System), an implantable LVAD that uses this technology to treat advanced heart failure patients. A second product, Nemo, extends the wave membrane technology to mini-invasive circulatory support applications. All products are currently investigational and not approved for commercial use.
Differentiator
Problem solved
Functional benefit
Products and services
- Wave Membrane A disruptive membrane technology that produces truly pulsatile blood flow by undulating like fish fins, replacing traditional rotary pumps and reducing friction and shear forces. Forms the technological basis for CorWave's LVAD and Nemo products.
- CorWave LVAS Left Ventricular Assist System (LVAD) using wave membrane technology. An implantable heart assist pump connected to the left ventricle, designed to treat patients with advanced heart failure by reproducing physiological pulse and blood flow velocities similar to a healthy heart. Currently an investigational device not approved for commercial use.
- Nemo A mini-invasive cardiac pump using wave membrane technology for circulatory support for heart conditions beyond LVAD applications. Extends CorWave's wave membrane platform to broader cardiac indications.
Quantifiable outcome
- Successfully completed first chronic 60-day preclinical study in 2019, followed by 90-day in vivo study in 2021 with native heart synchronization
- +1 more outcomes
Companies that use Corwave
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Corwave technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Corwave partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Lille University Hospital (CHU de Lille)coreClinical R&D partner for the CALYPSO program, working on CorWave LVAD development for severe heart failure patients. Part of a PSPC (Structuring Project for Competitive Solutions) funded by Bpifrance.
- AP-HP Pitié-Salpêtrière HospitalcoreClinical R&D partner for the CALYPSO program alongside Lille University Hospital. Key cardiac surgery center involved in CorWave device development and testing.
- MD StartcoreStartup studio that founded CorWave in 2012 with exclusive license agreement with AMS R&D for the wave membrane technology. Led by Gérard Hascoët and Tim Lenihan.
Scale indicators6 records
Recent moves8 records
Expansion highlights5 records
Corwave competitors and assessment
Company assessmentBroad incumbents
- Abbott: Abbott acquired Thoratec and markets HeartMate 3, the dominant continuous-flow LVAD and CorWave's primary direct competitor. Comparable because it sells into the same cardiac surgery / advanced heart failure call point with an implantable mechanical circulatory support device, but operates a broad diagnostics and device portfolio.
- Medtronic: Previously commercialized the HVAD LVAD (acquired via HeartWare; HVAD withdrawn in 2021) and remains active in cardiac surgery and heart failure. Comparable as a major cardiac device incumbent that has shipped LVAD-class products to the same surgical centers CorWave targets.
Direct peers
- Carmat: French clinical-stage company developing a total artificial heart for end-stage biventricular heart failure. Comparable as a French, clinical-stage cardiac assist implant developer targeting the same advanced heart failure patient population and surgeon customer base.
- SynCardia Systems: US-based developer of the SynCardia total artificial heart, the most widely implanted TAH in the world. Comparable as a developer of a mechanical implantable cardiac assist device serving end-stage heart failure patients treated by cardiac surgeons.
- Abiomed (Johnson & Johnson MedTech): Now part of J&J MedTech, Abiomed markets the Impella family of percutaneous mechanical circulatory support devices used in high-risk PCI and cardiogenic shock. Comparable as a mechanical circulatory support franchise addressing advanced heart failure and cardiac surgery patients, though percutaneous rather than implantable.
- Evaheart: Japanese company developing a next-generation implantable LVAD using a centrifugal, hydrodynamically suspended impeller, currently in clinical use in Japan and pursuing US approval. Comparable as a developer of a novel implantable LVAD competing against HeartMate 3 in the same surgical indication.
- Berlin Heart: German manufacturer of the EXCOR ventricular assist device, primarily used as a pediatric and bridge-to-transplant VAD. Comparable as a European mechanical circulatory support company selling implantable VADs to cardiac surgeons and heart failure specialists.
Emerging players
- Calon Cardio-Technology: UK-based early-stage company developing a next-generation miniaturised rotary LVAD. Comparable as a small European LVAD developer pursuing a pulsatile/low-shear design thesis similar to CorWave's, targeting the same advanced heart failure implant market.
Others
- LivaNova: Cardiac surgery and neuromodulation device company with a legacy in cardiopulmonary bypass and heart valves. Comparable as a cardiac surgery device peer relevant to CorWave's hospital procurement and cardiac surgeon customer channel, though not an LVAD competitor.
- Cirtec Medical: US-based contract manufacturer specializing in active implantable medical devices, including components for ventricular assist devices. Comparable as a supplier/manufacturing partner in the LVAD supply chain rather than a direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Corwave social profiles
Digital presenceCorwave compliance and trust
Trust signalCompliance1 record
Corwave financial estimates
Financial estimateRevenue estimate
Valuation estimate
Corwave leadership team
Management profileNumber of profiles
Profiles12 records
Corwave funding detail
Funding detailFunding overview
Funding rounds9 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Corwave M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Corwave
What does Corwave do?
CorWave is a clinical-stage medical device company developing implantable cardiac assist pumps based on its proprietary wave membrane technology. The flagship offering is the CorWave LVAS (Left Ventricular Assist System), an implantable LVAD that uses an undulating membrane to produce physiological pulsatile blood flow for patients with advanced heart failure. A second product, Nemo, extends the wave membrane platform to mini-invasive circulatory support applications. All products are currently investigational and not approved for commercial use in any country.
Is Corwave a public or private company?
Corwave is a private company. It is classified as venture growth investor backed and is currently operating.
When was Corwave founded?
Corwave was founded in 2012. It employs 51 to 100 people.
Where is Corwave based?
Corwave is headquartered in Paris, France, in the Europe region.
How does Corwave make money?
One revenue line is on record: cardiac Assist Devices (pre-commercial).
Who are Corwave's main competitors?
Broad incumbents on record are Abbott and Medtronic. Direct peers are Carmat, SynCardia Systems, Abiomed (Johnson & Johnson MedTech), Evaheart and Berlin Heart. Calon Cardio-Technology is listed as an emerging player. Others are LivaNova and Cirtec Medical.
Does Corwave have an API?
No public API is recorded for Corwave.
What industry is Corwave in?
Corwave's product category is Cardiac Assist Devices (LVAD). Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.